KR-30450

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 529815

CAS#: 172489-10-0

Description: KR-30450 is potassium channel agonist potentially for the treatment of hypertension.

Chemical Structure

img
KR-30450
CAS# 172489-10-0
Instruction

Theoretical Analysis

MedKoo Cat#: 529815
Name: KR-30450
CAS#: 172489-10-0
Chemical Formula: C17H18N2O6
Exact Mass: 346.12
Molecular Weight: 346.339
Elemental Analysis: C, 58.96; H, 5.24; N, 8.09; O, 27.72

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: KR-30450; SKP-450; KR30450; SKP450; KR 30450; SKP 450

IUPAC/Chemical Name: (R)-1-(2-(1,3-dioxolan-2-yl)-2-methyl-6-nitro-2H-chromen-4-yl)pyrrolidin-2-one

InChi Key: NJJPKIPOZSWUHV-QGZVFWFLSA-N

InChi Code: InChI=1S/C17H18N2O6/c1-17(16-23-7-8-24-16)10-13(18-6-2-3-15(18)20)12-9-11(19(21)22)4-5-14(12)25-17/h4-5,9-10,16H,2-3,6-8H2,1H3/t17-/m1/s1

SMILES Code: O=C1N(C2=C[C@](C)(C3OCCO3)OC4=C2C=C([N+]([O-])=O)C=C4)CCC1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 346.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Jung YS, Moon CH, Cho TS, Yoo SE, Shin HS. Cardioprotective effects of KR-30450, a novel K+(ATP) opener, and its major metabolite KR-30818 on isolated rat hearts. Jpn J Pharmacol. 1998 Jan;76(1):65-73. PubMed PMID: 9517406.

2: Kwak YG, Park SK, Kang HS, Kim JS, Chae SW, Cho KP, Yoo SE, Kim D. KR-30450, a newly synthesized benzopyran derivative, activates the cardiac ATP-sensitive K+ channel. J Pharmacol Exp Ther. 1995 Nov;275(2):807-12. PubMed PMID: 7473170.

3: Kwan YW, To KW, Lau WM, Tsang SH. Comparison of the vascular relaxant effects of ATP-dependent K+ channel openers on aorta and pulmonary artery isolated from spontaneously hypertensive and Wistar-Kyoto rats. Eur J Pharmacol. 1999 Jan 22;365(2-3):241-51. PubMed PMID: 9988108.

4: Shin HS, Seo HW, Oh JH, Lee BH. Antihypertensive effects of the novel potassium channel activator SKP-450 and its major metabolites in rats. Arzneimittelforschung. 1998 Oct;48(10):969-78. PubMed PMID: 9825113.

5: Jang IJ, Yu KS, Shon JH, Bae KS, Cho JY, Yi SY, Shin SG, Ryu KH, Cho YB, Kim DK, Yoo SE. Pharmacokinetic/pharmacodynamic evaluation of a novel potassium channel opener, SKP-450, in healthy volunteers. J Clin Pharmacol. 2000 Jul;40(7):752-61. PubMed PMID: 10883417.

6: Kim HH, Yoo SE, Lee WS, Rhim BY, Hong KW. SKP-450 inhibits migration and DNA synthesis stimulated by oxidized low density lipoprotein in smooth muscle cells. Eur J Pharmacol. 1999 Nov 3;383(3):373-9. PubMed PMID: 10594331.

7: Hong KW, Shin HS, Kim CD, Shin YW, Yoo Se. Pharmacological profiles of SKP-450 and its family, a K+ channel opener, in comparison with levcromakalim. Pharmacol Res. 1998 Sep;38(3):191-7. PubMed PMID: 9782069.

8: Cheon HG, Kim HJ, Mo HK, Yoo SE, Lee BH. Anti-ulcer activity of SKP-450, a novel potassium channel activator, in rats. Pharmacol Res. 1999 Sep;40(3):243-8. PubMed PMID: 10479468.

9: Baek M, Chung HS, Kim Y, Kim DH. Disposition and metabolism of 2-(2''(1'',3''-dioxolan-2-yl)-2- methyl-4-(2'-oxopyrrolidin-1-Yl)-6-nitro-2h-1-benzopyran (SKP-450) in rats. Drug Metab Dispos. 1999 Apr;27(4):510-6. PubMed PMID: 10101146.

10: Lee EY, Lim DM, Yoo SE, Kim DK, Paik YK. Biochemical basis for a cholesterol-lowering activity of 2-[2"-(1",3"-dioxolane)]-2-methyl-4-(2'-oxo-1'-pyrrolidinyl)-6- nitro-2H-1-benzopyran (SKP-450), a novel antihypertensive agent. Biochem Pharmacol. 1999 Mar 1;57(5):579-82. PubMed PMID: 9952322.

11: Shin HS, Seo HW, Yoo SE, Lee BH. Cardiovascular pharmacology of SKP-450, a new potassium channel activator, and its major metabolites SKP-818 and SKP-310. Pharmacology. 1998 Mar;56(3):111-24. PubMed PMID: 9532610.

12: Lee BH, Yoo SE, Shin HS. Hemodynamic profile of SKP-450, a new potassium-channel activator. J Cardiovasc Pharmacol. 1998 Jan;31(1):85-94. PubMed PMID: 9456282.